Ads
related to: statins don't increase survivability due to cancer symptoms infection
Search results
Results From The WOW.Com Content Network
Alternative uses for statins for other health conditions are an ongoing area of research. Effects of statins on inflammation, cancer. Researchers of the current study note that chronic ...
Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. [3] CK levels increase to 10-100 times above normal (2000–20,000 IU/L) in more than 90% of cases.
Clinical studies have been conducted on the use of statins in dementia, [215] lung cancer, [216] nuclear cataracts, [217] hypertension, [218] [219] and prostate cancer [220] and breast cancer. [221] There is no high quality evidence that statins are useful for pneumonia . [ 222 ]
The link between liver cancer and high cholesterol is fatty liver disease. ... Bile acid sequestrates appeared to slightly increase, by 5.31%, the chance of liver cancer, though the researchers ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
For premium support please call: 800-290-4726 more ways to reach us
The risk of myopathy may be increased in Asian Americans: "Because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side effects, a study by the drug's manufacturer, AstraZeneca, indicated."
[40] [9] Due to the prevalence of infection by H. pylori in middle-aged adults (74% in developing countries and 58% in developed countries in 2002 [41]), and 1% to 3% likelihood of infected individuals developing gastric cancer, [42] H. pylori-induced gastric cancer is the third highest cause of worldwide cancer mortality as of 2018.